版本:
中国

BRIEF-Pfizer receives FDA fast track designation for Tafamidis for transthyretin cardiomyopathy

June 6 Pfizer Inc

* Pfizer receives FDA fast track designation for tafamidis for transthyretin cardiomyopathy

* Pfizer Inc - ‍Tafamidis, an investigational medicine for ttr-cm, is currently in phase 3 development​

* Pfizer Inc - ‍attr-act study is fully enrolled and is anticipated to be completed in first half of 2018​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐